PRESS RELEASE:

LabVantage Pharma now available for Indian Market

Somerset, NJ – September 2, 2015 – LabVantage Solutions, the leading global laboratory informatics provider, today announced the general availability of LabVantage Pharma for the Indian market. LabVantage Pharma is a pre-validated, preconfigured pharmaceutical LIMS. LabVantage Pharma provides the fast growing Indian pharmaceutical industry with a way to comply with USFDA regulations as well as improve lab efficiency.

Pharmaceutical companies need a Laboratory Information Management System (LIMS) to improve quality, stay compliant with regulations and increase efficiency. Traditionally, LIMS implementation has been long and expensive. LabVantage is the first company to introduce a pre-validated, preconfigured LIMS that can be implemented in as little as three months. LabVantage Pharma provides laboratories with a pre-validated solution according to GAMP 5 guidelines. Laboratories with limited resources looking for a cost effective, FDA compliant LIMS solution will find LabVantage Pharma ideal.

Dozens of labs in the United States and Europe have already implemented LabVantage Pharma. Piramal Enterprise Limited (PEL), one of the leading players globally in CRAMS (custom research and manufacturing services) is one of the early adopters of LabVantage in India. With LabVantage in place, PEL is manufacturing products for the global market while staying compliant with FDA regulations.

Dr. Purnendu Chatterjee, Chairman of the Chatterjee Group, parent company of LabVantage stated, “We want to help Indian pharmaceutical companies compete in the global market. We see the FDA increasing its scrutiny of Indian pharma companies with a number of them receiving the FDA form 483 recently. With LabVantage Pharma, we have provided a proven, industry leading solution to stay compliant. In addition, this solution dramatically reduces the time for customers to go live with their implementation. The response to LabVantage Pharma has been very positive globally and we expect the momentum to continue in India.”

New Picture (2)